Literature DB >> 22249269

c-Jun N-terminal kinase has a pivotal role in the maintenance of self-renewal and tumorigenicity in glioma stem-like cells.

C-H Yoon1, M-J Kim, R-K Kim, E-J Lim, K-S Choi, S An, S-G Hwang, S-G Kang, Y Suh, M-J Park, S-J Lee.   

Abstract

Uncovering the mechanisms that govern the maintenance of stem-like cancer cells is critical for developing therapeutic strategies for targeting these cells. Constitutive activation of c-Jun N-terminal kinase (JNK) has been reported in gliomas and correlates with histological grade. Here, we found that JNK signaling is crucial for the maintenance of 'stemness' in glioma cells. Sphere-cultured glioma cells showed more phosphorylation of JNK compared with serum-containing monolayer cultures. Importantly, blockade of JNK signaling with SP600125 or small interfering RNAs targeting JNK1 or JNK2 significantly reduced the CD133(+)/Nestin(+) population and suppressed sphere formation, colony formation in soft agar, and expression of stem cell markers in sphere-cultured glioma cells. Intriguingly, sphere-cultured glioma cells exhibited enhanced expression of Notch-2, but not Notch-1, -3 or -4, and JNK inhibition almost completely abrogated this increase. Blocking the phosphoinoside 3-kinase (PI3K)/Akt pathway with LY294002 or si-Akt also suppressed the self-renewal of sphere-cultured glioma cells. PI3K, but not Akt, had a role as an upstream kinase in JNK1/2 activation. In addition, treatment with si-JNK greatly increased etoposide- and ionizing radiation (IR)-induced cell death in glioma spheres. Consistent with glioma cell lines, glioma stem-like cells isolated from primary patient glioma cells also had a higher activity of JNK and Notch-2 expression. Importantly, inhibition of JNK2 led to a decrease of Notch-2 expression and suppressed the CD133(+)/Nestin(+) cell population in patient-derived primary glioma cells. Finally, downregulation of JNK2 almost completely suppressed intracranial tumor formation by glioma cells in nude mice. Taken together, these data demonstrate that JNK signaling is crucial for the maintenance of self-renewal and tumorigenicity of glioma stem-like cells and drug/IR resistance, and can be considered a promising target for eliminating stem-like cancer cells in gliomas.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22249269     DOI: 10.1038/onc.2011.634

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  52 in total

Review 1.  JNK signalling in cancer: in need of new, smarter therapeutic targets.

Authors:  Concetta Bubici; Salvatore Papa
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

Review 2.  JNK Signaling: Regulation and Functions Based on Complex Protein-Protein Partnerships.

Authors:  András Zeke; Mariya Misheva; Attila Reményi; Marie A Bogoyevitch
Journal:  Microbiol Mol Biol Rev       Date:  2016-07-27       Impact factor: 11.056

Review 3.  JNK signaling as a target for anticancer therapy.

Authors:  Kamal S Abdelrahman; Heba A Hassan; Salah A Abdel-Aziz; Adel A Marzouk; Atsushi Narumi; Hiroyuki Konno; Mohamed Abdel-Aziz
Journal:  Pharmacol Rep       Date:  2021-03-12       Impact factor: 3.024

4.  PKCδ maintains phenotypes of tumor initiating cells through cytokine-mediated autocrine loop with positive feedback.

Authors:  R-K Kim; Y Suh; E Hwang; K-C Yoo; K-S Choi; S An; S-G Hwang; I-G Kim; M-J Kim; H-J Lee; S-J Lee
Journal:  Oncogene       Date:  2015-03-09       Impact factor: 9.867

Review 5.  Brain tumor stem cells: Molecular characteristics and their impact on therapy.

Authors:  David L Schonberg; Daniel Lubelski; Tyler E Miller; Jeremy N Rich
Journal:  Mol Aspects Med       Date:  2013-07-04

6.  MDM2 Degrades Deacetylated Nucleolin Through Ubiquitination to Promote Glioma Stem-Like Cell Enrichment for Chemotherapeutic Resistance.

Authors:  Chiung-Yuan Ko; Chao-Han Lin; Jian-Ying Chuang; Wen-Chang Chang; Tsung-I Hsu
Journal:  Mol Neurobiol       Date:  2017-05-06       Impact factor: 5.590

7.  Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines.

Authors:  Joshua C Anderson; Christine W Duarte; Karim Welaya; Timothy D Rohrbach; Markus Bredel; Eddy S Yang; Nirmal V Choradia; Jaideep V Thottassery; George Yancey Gillespie; James A Bonner; Christopher D Willey
Journal:  Radiother Oncol       Date:  2014-05-08       Impact factor: 6.280

Review 8.  Eph receptor tyrosine kinases in cancer stem cells.

Authors:  Jin Chen; Wenqiang Song; Katherine Amato
Journal:  Cytokine Growth Factor Rev       Date:  2014-05-17       Impact factor: 7.638

9.  c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun.

Authors:  X Xie; T S Kaoud; R Edupuganti; T Zhang; T Kogawa; Y Zhao; G B Chauhan; D N Giannoukos; Y Qi; D Tripathy; J Wang; N S Gray; K N Dalby; C Bartholomeusz; N T Ueno
Journal:  Oncogene       Date:  2016-12-12       Impact factor: 9.867

10.  Tumor-specific activation of the C-JUN/MELK pathway regulates glioma stem cell growth in a p53-dependent manner.

Authors:  Chunyu Gu; Yeshavanth K Banasavadi-Siddegowda; Kaushal Joshi; Yuko Nakamura; Habibe Kurt; Snehalata Gupta; Ichiro Nakano
Journal:  Stem Cells       Date:  2013-05       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.